Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial.

@article{Hu2015SafetyAE,
  title={Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial.},
  author={Xinyang Hu and Xin Huang and Qian Yang and Lihua Wang and Jianzhong Sun and Hongwei Zhan and Jianjing Lin and Zhaoxia Pu and Jun Jiang and Yong Mei Sun and Meixiang Xiang and Xianbao Liu and Xiaojie Xie and Xia Yu and Zexin Chen and Hung-Fat Tse and Jianyi Jay Zhang and Jian'an Wang},
  journal={International journal of cardiology},
  year={2015},
  volume={184},
  pages={446-51}
}
BACKGROUND Pre-clinical studies have shown that hypoxia preconditioning can enhance stem cell therapeutic potential for myocardial repair. We sought to investigate the safety and feasibility of intracoronary administration of hypoxia-preconditioned bone marrow mononuclear cells (HP-BMCs) for acute ST segment elevation myocardial infarction (STEMI… CONTINUE READING